medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2021, Number 2

<< Back Next >>

Revista Cubana de Salud Pública 2021; 47 (2)

Resistance of Mycobacterium tuberculosis to quinolone and injectable drugs in Atlántico department, 2013-2016

Ruíz MLFJ, Arzuza OL, Guerra SM, Parga LCH, Calonge-Solano CD

Language: Spanish
References: 28
Page: 1-20
PDF size: 1253.20 Kb.


ABSTRACT

Introduction: In Atlántico department, resistance studies of Mycobacterium tuberculosis have been limited to second-line drugs.
Objective: Determine prevalence of resistance to amikacin, kanamycin, capreomycin and ofloxacin in cases of tuberculosis resistant to isoniazid, rifampicin or both, in the period 2013 to 2016 in Atlántico department.
Methods: Cross-sectional study of 194 isolations resistant to isoniazid, rifampicin or both, by Genotype MTBDR plus version 2 methodology, that were sent to the National Institute of Health from 2013 to 2016 to be confirmed and processed for second-line drugs. The resistance ratio was made according to sociodemographic, clinical and public health surveillance variables.
Results: The common comorbilities found were malnutrition with 18.56%, followed by concomitant HIV-tuberculosis infection with 13.40%. Ofloxacin in non-treated cases achieved the highest overall resistance with 1.50% (95% CI 0.18-5.33). In those previously treated, global resistance to capreomycin was 8.10% (95% CI 2.7-17.8). In the ones resistant to rifampicin, one case was extensively resistant and two cases were resistant in multi-drugs resistant.
Conclusions: Low resistance to fluoroquinolones and injectable drugs was found in non-treated patients who were resistant to isoniazid, rifampicin or both, showing that it is not yet a major problem in Atlántico department. Its follow-up should be complemented with good physical and psychological management and a strengthened health team that acts promptly and helps the patient adherence to treatments.


REFERENCES

  1. Ordóñez S, López F. Tuberculosis en Colombia, de la historia al entendimiento de la enfermedad. MedUNAB. 2014 [acceso 29/02/2018];16(3):127-42. Disponible en: https://revistas.unab.edu.co/index.php/medunab/article/download/2084/1872/

  2. Caminero JA, Matteelli A, Loddenkemper R. Tuberculosis: Are we making it incurable? Eur Respir J. 2013;42(1):5-8. DOI: 10.1183/09031936.00206712

  3. Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, et al. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS ONE. 2016;11(5):e0155968 1-10. DOI: 10.1371/journal.pone.0155968

  4. Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, Raviglione MC, Kochi A. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis. 1994 Feb;75(1):1-7. DOI: 10.1016/0962-8479(94)90096-5

  5. Zabaleta A, Llerena C. Serie de casos: tuberculosis extremadamente resistente a drogas en Colombia, 2006-2016. Biomédica. 2019;39(4):707-14. DOI: 10.7705/biomedica.4842

  6. Caminero J. Multidrug-resistant tuberculosis: Epidemiology, risk factor and case finding. Int J Tuberc Lung Dis. 2010 [acceso 29/02/2018];14(4):382-90. Disponible en https://www.ncbi.nlm.nih.gov/pubmed/20202293

  7. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali, et al. Determinantes de la tuberculosis farmacorresistente: análisis de 11 países. Int J Tuberc Lung Dis. 2001 [acceso 04/01/2018];5(10):887-93. Disponible en: https://www.theunion.org/journals/french/article/ijtld_spanish_december2005.pdf

  8. World Health Organization, Global tuberculosis report-2017; Ginebra: WHO; 2017 [acceso 04/01/2018]. Disponible en: https://reliefweb.int/report/world/global-tuberculosis-report-2017

  9. Fadul S. Instituto Nacional de Salud, informe del evento tuberculosis farmacorresistente periodo epidemiológico IX, Colombia. Colombia: INS; 2017. [acceso 04/01/2018]. Disponible en: Disponible en: https://www.ins.gov.co/buscador-eventos/Paginas/Info-Evento.aspx

  10. World Health Organization. Global. Tuberculosis Report 2018. Reporte. Geneva: WHO; 2018. [acceso 04/01/2018]. Disponible en: Disponible en: https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?sequence=1&isAllowed=y

  11. Salud INd. Informe de evento de Tuberculosis, Colombia, 2018. Bogotá, D.C; 2018.

  12. Instituto Nacional de Salud. Informe de evento Tuberculosis Farmacorresistencia, Colombia, 2018. Bogotá, D.C: Cundinamarca; 2018.

  13. Torres C, Awad C, Dennis R, Varón F. Lineamiento para el manejo programático de pacientes con tuberculosis farmacorresistente. Colombia: Minsalud; 2013 p. 1-223. [acceso 04/01/2018]. Disponible en: Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/.../lineamientos-tb-farmacorresistente.pdf

  14. Llerena C, Rojas M. Informe de actividades realizadas por la Red Nacional de Laboratorios para la vigilancia de la resistencia de Mycobacterium tuberculosis a los fármacos antiuberculosos. Colombia: INS; 2013. [acceso 04/01/2018]. Disponible en: Disponible en: https://www.ins.gov.co/buscador-eventos/Informacin%20de%20laboratorio/Informe%20vigilancia%20de%20resistencia%20de%20Mycobacterium%20tuberculosis.pdf

  15. Fadul S, López M. Protocolo de Vigilancia en Salud Pública. Tuberculosis. Bogotá, Colombia: Dirección de Vigilancia y Análisis del Riesgo en Salud Pública; 2016. [acceso 01/02/2018]. Disponible en: Disponible en: https://www.casanare.gov.co/Dependencias/Salud/Normas%20yo%20lineamientos%20TB%20sensible%20TBFR%20TB%20latente/5.%20Protocolo%20de%20vigilancia%20en%20salud%20p%C3%BAblica%20para%20(Tuberculosis%20sensible).pdf

  16. Navas E, Moreno S. Tuberculosis multirresistente y extremadamente resistente. Rev esp sanid Penit. 2010;12(3):91-8. DOI: 10.4321/s1575-06202010000300005

  17. Alvis NJ, Carrasquilla M, Jhajaira V, Robledo J, Alvis NR, Hernández JM. Precisión diagnóstica de tres pruebas moleculares para detectar la tuberculosis multirresistente. Biomédica. 2017;37(3)97-407. DOI: 10.7705/biomedica.v37i3.3437

  18. Günther G, Van F, Alexandru S, Altet N, Avsar K, Bang D, et al. Multidrug-Resistant Tuberculosis in Europe, 2010-2011. Emerg Infect Dis. 2015;21(3):409-416. DOI: 10.3201/eid2103.141343

  19. Ministerio de Salud y Protección Social. Circular 001 del 8 de enero de 2013. Lineamientos para el manejo programático de los medicamentos de segunda línea para tuberculosis; 2003. [acceso 01/02/2018]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/circular-001-2013.pdf

  20. Llerena C, Zabaleta A, Valbuena A, Murcia M. Prevalencia de la resistencia de Mycobacterium tuberculosis a quinolonas y fármacos inyectables en Colombia, 2012-2013. Biomédica 2017;37(1):96-103. DOI: 10.7705/biomedica.v37i2.3204

  21. Caminero JA. Likely hood of generating MDR-TB and XDR-TB under adequate national Tuberculosis control programme implementation. Int J Tuberc Lung. 2008 [acceso 05/02/2018];12(8):869-77. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18647445

  22. Barletta F, Zamudio C, Rigouts L, Seas C. Resistencia a drogas de segunda línea en cepas peruanas de Mycobacterium tuberculosis multidrogorresistentes. Rev perú med exp salud pública 2014 [acceso 08/04/2018];31(4):676-82. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342014000400009&lng=es

  23. Mendoza A, Gotuzzo E. Tuberculosis extremadamente resistente (TB-XDR), historia y situación actual. Acta Médica Peruana. 2008 [acceso 23/05/2018];25(4):236-46. Disponible en: http://www.redalyc.org/articulo.oa?id=96625411

  24. Ahmad N, Javaid A, Sulaiman SAS, Ming LC, Ahmad I, Khan AH. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis 2016;20(1). DOI: 10.1016/j.bjid.2015.09.011

  25. Hu Y, Xu L, He YL, Pang Y, Lu N, Liu J, et al. Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China. BioMed Research International. 2017;(2017):1-9. DOI: 10.1155/2017/4563826

  26. Ghafoor A, Mehraj J, Afridi ND, Rafiq Y, Wendl HU, Hasan R. Multidrugresistant Mycobacterium tuberculosis amongst Category I & amp; II failures and Category II relapse patients from Pakistan.Int J Mycobacteriol. 2012;1(3):118-23. DOI: 10.1016/j.ijmyco.2012.07.004

  27. Cremades R, Rodríguez JC, Galiana A, Royo G. Frecuencia de la resistencia a fluoroquinolonas en Mycobacterium tuberculosis en Elche (Alicante). Enferm Infecc Microbiol Clin. 2014;32(5):337-8. DOI: 10.1016/j.eimc.2013.08.004

  28. Coll P. Farmacos con actividad frente a Mycobacterium tuberculosis. Enferm Infecc Microbiol Clin. 2009;27(8):474-80. DOI: 10.1016/j.eimc.2009.06.010




2020     |     www.medigraphic.com